Methotrexate (MTX), a disease-modifying anti-rheumatic drug (DMARD), induces an increased production of IL-10 in RA patients with a better therapeutic response (60) and is able to enhance HLA-G secretion by peripheral blood mononuclear cells (61). Here, HLA-G is linked to rheumatoid arthritis.